421 Somerville Avenue, #1-A Somerville, MA 02143 |
[P] (617) 764-4620 [F] (617) 764-4620 |
http://www.cancerpolicyinstitute.org [email protected] Ellie Okada, Ph.D. |
|
INCORPORATED: 2012
Printable Profile (Summary / Full) EIN 45-5124662 |
![]() LAST UPDATED: 07/10/2017 |
Organization DBA |
Boston Cancer Policy Institute |
---|---|
Former Names | -- |
Organization received a competitive grant from the Boston Foundation in the past five years | No |
--
|
Mission StatementMORE »Our missions are: (i) to conduct policy-oriented research on a mechanism that will advance paths towards individualizing cancer therapeutics and diagnostics, especially for metastasized/ rare cancers; and (ii) to contribute to improving cancer/ science policy outcomes for public interests.
Our focus is new social sciences. Our objective is not necessarily making policy recommendations. What we aim is to pursue logic and concepts that underlie features of events, which are relevant to policy questions. New social sciences encompass studies on science organizations, universities, transnationals, cancer/ science policies, care delivery system, institutions, intellectual property, among others. |
Mission StatementOur missions are: (i) to conduct policy-oriented research on a mechanism that will advance paths towards individualizing cancer therapeutics and diagnostics, especially for metastasized/ rare cancers; and (ii) to contribute to improving cancer/ science policy outcomes for public interests.
Our focus is new social sciences. Our objective is not necessarily making policy recommendations. What we aim is to pursue logic and concepts that underlie features of events, which are relevant to policy questions. New social sciences encompass studies on science organizations, universities, transnationals, cancer/ science policies, care delivery system, institutions, intellectual property, among others. |
Fiscal Year | Jan 01, 2016 to Dec 31, 2016 |
---|---|
Projected Income | $750.00 |
Projected Expense | $750.00 |
For more details regarding the organization's financial information, select the financial tab and review available comments.
Overall description of organization: A research institute of new social sciences, dedicated to conducting policy relevant research for public interests. Our activities are writing/ presenting research results at peer -reviewed/professional conferences and journals.
Accomplishment:
National
International
GREATER BOSTON REGION, MA
No
This program is to research mechanisms on advancing translational medicine from social science perspectives. Translational medicine and biomarkers are expected to play a
critical role in predicting clinical outcomes and diagnostics. They have shown effectiveness in addressing metastasized/rare cancers, and are expanding the field to include infections caused, and other molecular mutation diseases. Our program is to seek successful policy, organizational, and institutional mechanisms which can also be transferrable to other disease fields.
|
|
Budget | $140,000.00 |
---|---|
Category | Social Science; General/Other |
Population Served | People/Families of People with Cancer US US& International |
Program Short-Term Success | Add tangible contributions per program to the fields. Tangible contributions will be realized through working papers that achieve milestones, peer- reviewed /professionally reviewed paper and presentation. |
Program Long-Term Success | Contribute, through unbiased social science research, that the systemic barriers and conflicts are resolved, as well as distributive justice of resources will be balanced. |
Program Success Monitored By | Program success will be monitored by peer-reviewed research communities with policy mindsets. |
Examples of Program Success | A part of research results was accepted to present at a peer-reviewed conference, Governance on Emerging Technologies, Law School, Arizona State University (May 2015); International Multidisciplinary Conference on Science and Technology held in Boston ( Sept 2014, postponed to Sept 2015). |
There
are still system issues to address that all the people with molecular mutations
can live their autonomous lives. Complications with infectious diseases still
affect vulnerable population. Some of cancer induced pains, such as neuropathic pain and cancer induced bone pain, are clinical challenges. In addition, so many people with serious terminal
illness still cannot receive adequate pain medicine as well as quality cares nearing their end of life (Institute of Medicine
2014). This program will to contribute to explore
frameworks that will resolve or mitigate unmet needs with regulatory policy, organizational and institutional
perspectives. |
|
Budget | $160,000.00 |
---|---|
Category | Social Science; General/Other Interdisciplinary Studies |
Population Served | US People/Families of People with Cancer US& International |
Program Short-Term Success |
Contribute, through unbiased research, that systemic issues are resolved.
|
Program Long-Term Success |
Contribute, through unbiased social science research, that all the people with molecular mutations can live their autonomous lives. Patients nearing their end of life are honored and receive quality care.
|
Program Success Monitored By | Academic, professional research communities, stakeholders, as well as wider range of related individuals with policy mindsets will monitor the progress. |
Examples of Program Success | Submitted a Statement of Commitment to Institute of Medicine (IOM), in responding IOM (2014) Dying in America: Improving Quality and Honoring Individual Preferences near the End of Life. Started studies that are committed to the recommendations. Enhanced awareness of ethics at a working group of Multi-Regional Clinical Trial Center at Harvard and the Brigham and Women's Hospital. The focus : Ethics principles/ Ethical frameworks. |
Based on the above two programs, the third program will analyze cancer /science policy formulation processes, explore actual patterns and desired mechanisms based on appropriate theoretical frameworks, discuss issues with related parties and policy makers, and seek successful directions. |
|
Budget | $150,000.00 |
---|---|
Category | Social Science; General/Other |
Population Served | US People/Families of People with Cancer US& International |
Program Short-Term Success | Mechanisms of specific science policies will be analyzed from observations, based on appropriate theoretical foundation. |
Program Long-Term Success | Successful mechanisms that will be transferrable to similar fields will be induced. |
Program Success Monitored By | Science policy and ethics research communities will monitor the progress. |
Examples of Program Success |
The opportunities are (1) awareness on precision and molecular marker increased. (2) Social science aspects including policy, organizational and institutional issues are began to be recognized. The major challenge is staffing. Our activities such as writing an academic paper and discussing at workshops, mainly at universities, are invisible. It takes a time to have a tangible result. We will continue knowledge exchange with people with relevant mindsets. |
CEO/Executive Director | Dr. Ellie Okada Ph.D. |
---|---|
CEO Term Start | Apr 2012 |
CEO Email | [email protected] |
CEO Experience | Dr. Ellie Okada, Senior Fellow, President. Ellie
Okada is an academia, social scientist, strategist. As the senior
fellow of the Research Institute, Dr. Okada is committed to putting her knowledge and
experience to use in exploring frameworks that will soundly and ethically translate
discoveries to clinical settings, and to population health. Ellie Okada holds a Ph.D. in Business Management from Kobe University’s Graduate School of Business Administration program (Equivalent to the U.S. regionally accredited university Ph.D.). She is part of one of the last generations that received the traditional type of degree, which requires 10 years of teaching experience as academia, a 300-page book publication, a 12-month investigation, and an oral examination. From 1988 until 2012, she taught and researched at the Yokohama National University. While a professor, she came to the U.S. to serve at both Columbia University and Harvard University. As a visiting scholar at Columbia, she researched workable configurations of internal and external intellectual property to leverage organizational capability change. During her work as an academic associate (Visiting Scholar) at Harvard, Okada began to incorporate elements of policy frameworks into the management theory. Recognized by the Japanese Government as an expert in her field, Okada served on the Japanese Cabinet Office’s Council for Science and Technology between 2007 and 2009, during which time she aided in synchronizing intellectual property guidelines in the advanced medical science for the U.S. and Japan. Also served expert as academia at the kick- off meeting of the OECD knowledge based capital project held in Washington D.C. In 2012, Ellie Okada resigned her position as a tenured full professor in order to pursue her research questions, an option only available in the United States. Now she is concentrating on continued research, initiating new research programs at the Boston Cancer Policy Institute.
|
Co-CEO | -- |
Co-CEO Term Start | -- |
Co-CEO Email | -- |
Co-CEO Experience |
|
Name | Start | End |
---|---|---|
-- | -- | -- |
Name | Title | Experience/Biography |
---|---|---|
Dr. Robert A. Adelson J.D. | Director, Governance Division, Chair of Boards |
Partner of Engel & Schultz, PC. Experienced lawyer, has long contributed to the institutional change of Massachusetts. Has familiarity with academic institutions and academic medicine. |
Mr. Joseph A. Richmond CPA | Director, Tresurer, Governance Division |
Principal at Joseph A. Richmond CPA PC. Has a long experience of auditing and advising nonprofit institutions. |
Award | Awarding Organization | Year |
---|---|---|
-- | -- | -- |
Affiliation | Year |
---|---|
-- | -- |
Member of state association of nonprofits? | No |
---|---|
Name of state association | -- |
External Assessment or Accreditation | Year |
---|---|
-- | -- |
--
Number of Full Time Staff | 1 |
---|---|
Number of Part Time Staff | 2 |
Number of Volunteers | 0 |
Number of Contract Staff | 0 |
Staff Retention Rate % | 100% |
Ethnicity | African American/Black: 0 Asian American/Pacific Islander: 0 Caucasian: 2 Hispanic/Latino: 0 Native American/American Indian: 0 Other: 1 Other (if specified): permanent resident |
---|---|
Gender | Female: 1 Male: 2 Not Specified 0 |
Organization has Fundraising Plan? | Yes |
---|---|
Organization has Strategic Plan? | Yes |
Years Strategic Plan Considers | 5 |
Management Succession Plan | Yes |
Business Continuity of Operations Plan | Yes |
Organization Policies And Procedures | Yes |
Nondiscrimination Policy | Yes |
Whistle Blower Policy | Yes |
Document Destruction Policy | Yes |
Directors and Officers Insurance Policy | No |
State Charitable Solicitations Permit | Yes |
State Registration | Yes |
Risk Management Provisions |
Management Reports to Board? | Yes |
---|---|
CEO Formal Evaluation and Frequency | Yes Annually |
Senior Management Formal Evaluation and Frequency | No N/A |
Non Management Formal Evaluation and Frequency | No Annually |
Board Chair | Dr. Robert A Adelson JD |
---|---|
Board Chair Company Affiliation | Engel and Schultz, PC |
Board Chair Term | Aug 2014 - Dec 2016 |
Board Co-Chair | Mr. Joseph A Richmond CPA |
---|---|
Board Co-Chair Company Affiliation | Joseph A. Richmond CPA PC |
Board Co-Chair Term | Aug 2014 - Dec 2016 |
Name | Company Affiliations | Status |
---|---|---|
Dr. Robert A Adelson Esq. | Engel & Schultz, LLP | Voting |
Dr. Marcia V Fournier Ph.D. | BIOARRAY Therapeutics | NonVoting |
Dr. Ellie Okada Ph.D. | Boston Cancer Policy Institute, Inc | Voting |
Mr. Joseph A Richmond C.P.A. | Joseph A. Richmond, CPA PC | Voting |
Name | Company Affiliations | Status |
---|---|---|
-- | -- | -- |
Name | Company Affiliations | Status |
---|---|---|
-- | -- | -- |
Name | Company Affiliations | Status |
---|---|---|
Dr Marcia V Fournier Ph.D. | BIOARRAY Therapeutics | NonVoting |
Ethnicity | African American/Black: 0 Asian American/Pacific Islander: 0 Caucasian: 2 Hispanic/Latino: 1 Native American/American Indian: 0 Other: 1 Other (if specified): Permanent Resident |
---|---|
Gender | Female: 2 Male: 2 Not Specified 0 |
Board Term Lengths | 2 |
---|---|
Board Term Limits | 10 |
Board Meeting Attendance % | 80% |
Written Board Selection Criteria | Yes |
Written Conflict Of Interest Policy | Yes |
Percentage of Monetary Contributions | 15% |
Percentage of In-Kind Contributions | 85% |
Constituency Includes Client Representation | Yes |
--
--
Fiscal Year | Jan 01, 2016 to Dec 31, 2016 |
---|---|
Projected Income | $750.00 |
Projected Expense | $750.00 |
Form 990s | |
Audit Documents | -- |
IRS Letter of Exemption |
Fiscal Year | 2015 | 2014 | 2013 |
---|---|---|---|
Total Revenue | $12,535 | $10,332 | $17,286 |
Total Expenses | $12,530 | $10,332 | $17,286 |
Fiscal Year | 2015 | 2014 | 2013 |
---|---|---|---|
Foundation and Corporation Contributions |
-- | -- | -- |
Government Contributions | $0 | $0 | $0 |
Federal | -- | -- | -- |
State | -- | -- | -- |
Local | -- | -- | -- |
Unspecified | -- | -- | -- |
Individual Contributions | $12,535 | $10,332 | $17,286 |
Indirect Public Support | -- | -- | -- |
Earned Revenue | -- | -- | -- |
Investment Income, Net of Losses | -- | -- | -- |
Membership Dues | -- | -- | -- |
Special Events | -- | -- | -- |
Revenue In-Kind | -- | -- | -- |
Other | -- | -- | -- |
Fiscal Year | 2015 | 2014 | 2013 |
---|---|---|---|
Program Expense | $10,270 | $8,279 | $15,343 |
Administration Expense | $1,589 | $1,476 | $1,942 |
Fundraising Expense | $671 | $567 | -- |
Payments to Affiliates | -- | -- | -- |
Total Revenue/Total Expenses | 1.00 | 1.00 | 1.00 |
Program Expense/Total Expenses | 82% | 80% | 89% |
Fundraising Expense/Contributed Revenue | 5% | 5% | 0% |
Fiscal Year | 2015 | 2014 | 2013 |
---|---|---|---|
Total Assets | $3,520 | $3,530 | $3,365 |
Current Assets | $1,504 | $1,514 | $1,528 |
Long-Term Liabilities | $0 | $500 | $1,165 |
Current Liabilities | $0 | $0 | $0 |
Total Net Assets | $3,520 | $3,030 | $2,199 |
Fiscal Year | 2015 | 2014 | 2013 |
---|---|---|---|
1st (Source and Amount) |
-- -- |
-- -- |
-- -- |
2nd (Source and Amount) |
-- -- |
-- -- |
-- -- |
3rd (Source and Amount) |
-- -- |
-- -- |
-- -- |
Endowment Value | -- |
---|---|
Spending Policy | Income Only |
Percentage(If selected) | -- |
Credit Line | No |
Reserve Fund | No |
How many months does reserve cover? | -- |
Are you currently in a Capital Campaign? | No |
---|---|
Capital Campaign Purpose | -- |
Campaign Goal | -- |
Capital Campaign Dates | - |
Capital Campaign Raised-to-Date Amount | -- |
Capital Campaign Anticipated in Next 5 Years? | -- |
Fiscal Year | 2015 | 2014 | 2013 |
---|---|---|---|
Current Ratio: Current Assets/Current Liabilities | -- | -- | -- |
Fiscal Year | 2015 | 2014 | 2013 |
---|---|---|---|
Long-term Liabilities/Total Assets | 0% | 14% | 35% |
No Other Documents currently available. |
The Impact tab is a section on the Giving Common added in October 2013; as such the majority of nonprofits have not yet had the chance to complete this voluntary section. The purpose of the Impact section is to ask five deceptively simple questions that require reflection and promote communication about what really matters – results. The goal is to encourage strategic thinking about how a nonprofit will achieve its goals. The following Impact questions are being completed by nonprofits slowly, thoughtfully and at the right time for their respective organizations to ensure the most accurate information possible.
ULTIMATE GOAL: Our target population is patients with metastasized / rare cancers. Ultimate goal is that systemic issues are resolved so that patients with metastasized/ rare cancers can live their autonomous lives and receive appropriate therapeutic and diagnostics. Also, patients with terminal cancers, elderly, as well as end-of-life patients of all ages can receive improved quality care.
With such vision, we are performing social science research on mechanisms to advance sound translation of cancer/science research at academic settings, as well as to improve quality of cares.
BACKGROUND: There are still biologically heterogeneous cancer patients who do not respond to standards of care. For example, the two- year survival rate of Bellini duct carcinoma is only 20 %. In case of Adenoid Cystic Carcinoma, while having an 89 % survival rate over a five-year period, patients often have recurrent cancer. Patients with cancer metastatic are more susceptible to infectious diseases and other comorbidities. Many of advanced cancer patients develop chronic pains. However, certain kinds of pains do not respond to standards of cares. In addition, fragmentation of care delivery still cause burdens to end-of-life patients.
The scientific/institutional advancement has been enabling us to target molecular level causes more precisely, as well as increasing predictive ability for clinical and diagnostics outcome. Such a system will benefit unmet needs as well as a society in a long run. At the same time, we mustn't forget the quality of cares.
Currently, there are several challenges to overcome. We will be committed to resolving issues in translating science, soundly.
DEFINITION OF OUR LONG TERM SUCCESS: There are several missing links in the paths that cancer sciences results are ultimately delivered to patients. Some of them are due to pure scientific issues. However, several pitfalls and fragmentation reside outside of natural science research scopes. This is the reason why we created Boston Cancer Policy Institute as a research institute of new social sciences.
We will seek mechanisms, as well as contribute to improving cancer/ science policies.
We define our success when we induce a meaningful conclusions and implications both in theoretical and practical senses.
HOW WE WILL KNOW IF WE HAVE BEEN SUCCESSFUL: When our hypothesis are validated based on social science methodologies, and when we can draw meaningful conclusions, we will know, we have been successful.
We will submit papers as well as present findings at peer-reviewed/ professionally reviewed journals and conferences. Thus, we will stimulate discussion that will lead to systemic changes to resolve unmet needs of metastasized/ rare cancers.